JP2002539089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539089A5 JP2002539089A5 JP2000599774A JP2000599774A JP2002539089A5 JP 2002539089 A5 JP2002539089 A5 JP 2002539089A5 JP 2000599774 A JP2000599774 A JP 2000599774A JP 2000599774 A JP2000599774 A JP 2000599774A JP 2002539089 A5 JP2002539089 A5 JP 2002539089A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- -1 4-methylpiperidinyl Chemical group 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000006302 indol-3-yl methyl group Chemical group [H]N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C12)C([H])([H])* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12081399P | 1999-02-19 | 1999-02-19 | |
| US60/120,813 | 1999-02-19 | ||
| PCT/US2000/004274 WO2000049037A1 (en) | 1999-02-19 | 2000-02-18 | Growth hormone secretagogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539089A JP2002539089A (ja) | 2002-11-19 |
| JP2002539089A5 true JP2002539089A5 (https=) | 2007-07-05 |
Family
ID=22392709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000599774A Pending JP2002539089A (ja) | 1999-02-19 | 2000-02-18 | 成長ホルモン分泌促進薬 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1153034B1 (https=) |
| JP (1) | JP2002539089A (https=) |
| CN (1) | CN1179972C (https=) |
| AR (1) | AR023369A1 (https=) |
| AT (1) | ATE375996T1 (https=) |
| AU (1) | AU765642B2 (https=) |
| BR (1) | BR0008321A (https=) |
| CA (1) | CA2362303A1 (https=) |
| CO (1) | CO5160260A1 (https=) |
| DE (1) | DE60036785D1 (https=) |
| IL (1) | IL144350A0 (https=) |
| PE (1) | PE20001468A1 (https=) |
| WO (1) | WO2000049037A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
| JP2003534377A (ja) | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬 |
| US6756385B2 (en) * | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| US20040106665A1 (en) * | 2000-10-13 | 2004-06-03 | Kress Thomas Joseph | Resolution process for preparation of substantially pure (r) and (s) enantiomers of 2-(4-nitroimidazolyl)-4-methodxyphenylpropionic acid and salts thereof |
| US7560490B2 (en) * | 2001-01-23 | 2009-07-14 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
| US7396846B2 (en) | 2002-04-09 | 2008-07-08 | Eli Lilly And Company | Growth hormone secretagogues |
| DK1730119T3 (da) * | 2004-03-23 | 2008-08-11 | Pfizer Prod Inc | Imidazolforbindelser til behandling af neurodegenerative forstyrrelser |
| AU2006293619A1 (en) | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| PL4010322T3 (pl) | 2019-08-09 | 2026-02-16 | Pfizer Inc. | Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| AU2022339841A1 (en) | 2021-09-01 | 2024-03-28 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107836A (en) * | 1992-12-11 | 1998-01-04 | Merck & Co Inc | Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them |
| WO1994013696A1 (en) * | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| WO1998016527A1 (en) * | 1996-10-15 | 1998-04-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzoxepine derivatives which promote release of growth hormone |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
-
2000
- 2000-02-17 CO CO00011043A patent/CO5160260A1/es unknown
- 2000-02-18 AU AU34968/00A patent/AU765642B2/en not_active Ceased
- 2000-02-18 IL IL14435000A patent/IL144350A0/xx unknown
- 2000-02-18 CA CA002362303A patent/CA2362303A1/en not_active Abandoned
- 2000-02-18 JP JP2000599774A patent/JP2002539089A/ja active Pending
- 2000-02-18 DE DE60036785T patent/DE60036785D1/de not_active Expired - Lifetime
- 2000-02-18 PE PE2000000127A patent/PE20001468A1/es not_active Application Discontinuation
- 2000-02-18 AR ARP000100708A patent/AR023369A1/es unknown
- 2000-02-18 AT AT00913536T patent/ATE375996T1/de not_active IP Right Cessation
- 2000-02-18 EP EP00913536A patent/EP1153034B1/en not_active Expired - Lifetime
- 2000-02-18 BR BR0008321-6A patent/BR0008321A/pt not_active IP Right Cessation
- 2000-02-18 WO PCT/US2000/004274 patent/WO2000049037A1/en not_active Ceased
- 2000-02-18 CN CNB008037035A patent/CN1179972C/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539089A5 (https=) | ||
| JP2001526218A5 (https=) | ||
| JP2008514732A5 (https=) | ||
| JP2003522724A5 (https=) | ||
| JP2002519425A5 (https=) | ||
| JP2003500442A5 (https=) | ||
| JP2004509061A5 (https=) | ||
| DE60128258D1 (de) | Indanylderivate zur Behandlung von Atemwegserkrankungen | |
| IL101162A0 (en) | Pharmaceutical compositions for oral administration comprising an indole derivative | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| RU95122775A (ru) | Способ уменьшения потерь костной ткани, способ лечения остеопороза и применение соединения | |
| JP2003503449A5 (https=) | ||
| DK1623703T3 (da) | Hydrocodonformuleringer med kontrolleret frigivelse | |
| JP2007507494A5 (https=) | ||
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| MY125099A (en) | Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid | |
| JP2003502367A5 (https=) | ||
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| JP2001520994A5 (https=) | ||
| CN1950076A (zh) | 含安溴索的局部制剂 | |
| JPH10147529A5 (https=) | ||
| DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| JP2003510255A5 (https=) | ||
| JP2002526550A5 (https=) |